Novateor Research Laboratories Ltd
Novateor Research Laboratories Ltd (NOVATEOR) last reported results for the quarter ended Mar 2026, with sales of ₹1.36 crore and net profit of ₹0.12 crore. The stock last traded at ₹37.5, a market capitalisation of ₹22.7 crore, on a P/E of 227. Over the past 52 weeks the stock has ranged between ₹20.1 and ₹37.5. Figures are as of 6 Oct 2026 and are not real time.
Novateor Research Laboratories Ltd share price and key metrics
- Current price
- ₹37.5
- Market cap
- ₹22.7 cr
- Stock P/E
- 227
- Book value
- ₹19
- ROE
- 0.91%
- ROCE
- 1.67%
- Dividend yield
- 0.00%
- 52w high / low
- 37.5/20.1
Metrics as of 6 Oct 2026. Not real time.
Track Novateor Research Laboratories Ltd
Cruxal reads every Novateor Research Laboratories Ltd filing as it lands, scores what it means for the stock, and emails you the ones that matter. Free to start.
Novateor Research Laboratories Ltd growth and returns
- 10 Years
- 44%
- 5 Years
- 82%
- 3 Years
- 45%
- TTM
- 38%
- 10 Years
- %
- 5 Years
- 58%
- 3 Years
- 36%
- TTM
- 25%
- 10 Years
- %
- 5 Years
- 19%
- 3 Years
- 5%
- 1 Year
- 43%
- 10 Years
- 1%
- 5 Years
- 1%
- 3 Years
- 1%
- Last Year
- 1%
Novateor Research Laboratories Ltd quarterly results
In the quarter ended Mar 2026, sales were ₹1.36 cr, down 31.3% from ₹1.98 cr a year earlier. Net profit was ₹0.12 cr, up 140.0% year on year.
| ₹ crore | Sep 2022 | Mar 2023 | Sep 2023 | Mar 2024 | Sep 2024 | Mar 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 0.82 | 0.44 | 0.36 | 0.85 | 0.79 | 1.98 | 2.47 | 1.36 |
| Expenses | 1.01 | 0.58 | 0.53 | 1 | 0.9 | 2 | 2.59 | 1.35 |
| Operating profit | -0.19 | -0.14 | -0.17 | -0.15 | -0.11 | -0.02 | -0.12 | 0.01 |
| OPM % | -23.17% | -31.82% | -47.22% | -17.65% | -13.92% | -1.01% | -4.86% | 0.74% |
| Other income | 0.24 | 0.25 | 0.24 | 0.24 | 0.24 | 0.24 | 0.25 | 0.24 |
| Interest | 0 | 0.03 | 0.02 | 0.01 | 0.02 | 0.05 | 0.05 | 0.04 |
| Depreciation | 0.04 | 0.04 | 0.04 | 0.04 | 0.06 | 0.1 | 0.09 | 0.09 |
| Profit before tax | 0.01 | 0.04 | 0.01 | 0.04 | 0.05 | 0.07 | -0.01 | 0.12 |
| Tax % | 0.00% | 0.00% | 0.00% | 0.00% | 20.00% | 28.57% | 100.00% | 8.33% |
| Net profit | 0.01 | 0.03 | 0.01 | 0.04 | 0.03 | 0.05 | -0.02 | 0.12 |
| EPS (₹) | 0.02 | 0.06 | 0.02 | 0.08 | 0.06 | 0.10 | -0.03 | 0.20 |
Consolidated figures as reported by the company. Percentages are as published; totals may not sum exactly.
Novateor Research Laboratories Ltd annual results
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 0.14 | 0.09 | 0.41 | 0.39 | 0.19 | 0.74 | 1.26 | 1.21 | 2.78 | 3.83 |
| Operating profit | 0.06 | 0.05 | 0.28 | -0.14 | -0.33 | -0.18 | -0.34 | -0.33 | -0.14 | -0.1 |
| OPM % | 42.86% | 55.56% | 68.29% | -35.90% | -173.68% | -24.32% | -26.98% | -27.27% | -5.04% | -2.61% |
| Net profit | 0 | 0 | 0.22 | -0.01 | 0.01 | -0.23 | 0.04 | 0.03 | 0.08 | 0.1 |
| EPS (₹) | 0.00 | 0.00 | 0.74 | -0.02 | 0.02 | -0.48 | 0.08 | 0.06 | 0.17 | 0.17 |
TTM is the trailing twelve months to the most recent quarter.
Novateor Research Laboratories Ltd balance sheet
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Equity capital | 0.05 | 0.05 | 2.96 | 4.83 | 4.83 | 4.83 | 4.83 | 4.83 | 4.83 | 6.05 |
| Reserves | 0.88 | 0.88 | 1.11 | 3.73 | 3.74 | 3.01 | 3.04 | 3.93 | 5.71 | 5.45 |
| Borrowings | 0.87 | 0.82 | 0.01 | 0.00 | 0.24 | 0.24 | 0.84 | 1.11 | 0.91 | 1.03 |
| Other liabilities | 0.10 | 0.09 | 0.24 | 0.23 | 0.17 | 0.06 | 0.24 | 0.59 | 1.16 | 1.74 |
| Total liabilities | 1.90 | 1.84 | 4.32 | 8.79 | 8.98 | 8.14 | 8.95 | 10.46 | 12.61 | 14.27 |
| Fixed assets | 1.66 | 1.59 | 3.55 | 3.45 | 3.36 | 1.94 | 1.78 | 2.43 | 3.41 | 3.24 |
| CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.43 | 0.44 | 0.00 | 0.00 |
| Investments | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 |
| Other assets | 0.23 | 0.24 | 0.76 | 5.33 | 5.61 | 6.19 | 6.73 | 7.58 | 9.19 | 11.02 |
| Total assets | 1.90 | 1.84 | 4.32 | 8.79 | 8.98 | 8.14 | 8.95 | 10.46 | 12.61 | 14.27 |
As reported by the company. Total assets equal total liabilities by construction.
Novateor Research Laboratories Ltd cash flow
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | 0.01 | 0.05 | -0.07 | -3.42 | -0.27 | -0.97 | -0.97 | -0.98 | -1.03 | -0.18 |
| Cash from investing | -0.01 | 0.00 | -1.96 | -0.10 | -0.09 | 0.91 | 0.13 | -0.25 | -0.22 | -0.50 |
| Cash from financing | 0.00 | -0.03 | 2.03 | 4.18 | 0.32 | -0.13 | 0.58 | 1.10 | 1.43 | 0.89 |
| Net cash flow | -0.01 | 0.02 | 0.00 | 0.67 | -0.04 | -0.18 | -0.26 | -0.13 | 0.18 | 0.20 |
| Free cash flow | 0.00 | 0.05 | -2.03 | -3.52 | -0.36 | -0.06 | -1.33 | -1.72 | -1.73 | -0.20 |
| CFO / operating profit | 17% | 100% | 0% | 2,443% | 82% | 539% | 285% | 297% | 736% | 180% |
Negative figures are outflows. CFO / operating profit is a ratio, not an amount.
Novateor Research Laboratories Ltd operating ratios
| Per year | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| ROCE % | 0.57% | 0.56% | 9.95% | 0.47% | 0.12% | 2.49% | 0.71% | 0.86% | 1.69% | 1.67% |
| Debtor days | 182.50 | 243.33 | 133.54 | 233.97 | 384.21 | 212.09 | 202.78 | 337.85 | 271.78 | 268.75 |
| Inventory days | 1,460.00 | 2,737.50 | 6,448.33 | 700.80 | 851.67 | 344.34 | 215.16 | 268.95 | 151.10 | 152.08 |
| Days payable | 730.00 | 1,095.00 | 1,460.00 | 14.60 | 104.29 | 20.66 | 61.47 | 207.47 | 176.61 | 208.57 |
| Cash conversion cycle | 912.50 | 1,885.83 | 5,121.87 | 920.17 | 1,131.59 | 535.77 | 356.46 | 399.32 | 246.27 | 212.26 |
| Working capital days | 286.79 | 527.22 | 462.93 | 4,117.95 | 9,067.37 | 2,747.36 | 1,604.84 | 1,879.30 | 950.58 | 770.98 |
Ratios as computed by the source from the reported statements. Rows a company does not report are omitted.
Novateor Research Laboratories Ltd shareholding pattern
Promoters held 50.75% at Mar 2026, down from 60.87% at Sep 2024.
| % held | Mar 2023 | Sep 2023 | Mar 2024 | Sep 2024 | Mar 2025 | May 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters | 60.87% | 60.87% | 60.87% | 60.87% | 60.87% | 51.60% | 50.90% | 50.75% |
| Public | 39.13% | 39.13% | 39.13% | 39.12% | 39.13% | 48.40% | 49.09% | 49.24% |
| No. of shareholders | 113 | 118 | 122 | 160 | 142 | 164 | 172 | 172 |
As disclosed by the company to the exchanges. The last row is a count of shareholders, not a percentage.
Novateor Research Laboratories Ltd corporate filings
- Company: Novateor Research Laboratories Limited - Voting Results of 15th AGM (2026)AGM/EGMmedium impact
Cruxal's analysis: Novateor Research Laboratories Limited held its 15th AGM on 29th September 2026, with…
Read the full analysis - The trading window for the trading in the securities of the company will remain closed with effect form October 01, 2026 for all the Directors, Designated Persons and their immediate relatives ....Insider Trading / SASTlow impact
- Novateor Research Laboratories Ltd changes registered office from Ahmedabad to Sanand, Gujarat, effective October 1, 2026Company Updatelow impact
Cruxal's analysis: The company has announced a change in its registered office address from 1026, Dev…
Read the full analysis - Company holds 15th AGM; no immediate financial disclosures or strategic updates providedAGM/EGMlow impact
Cruxal's analysis: Novateor Research Laboratories Limited conducted its 15th Annual General Meeting on 29th…
Read the full analysis - Novateor Research Laboratories Ltd releases Annual Report for FY 2025-26Otherslow impact
Cruxal's analysis: Novateor Research Laboratories has filed its Annual Report for the financial year…
Read the full analysis - Novateor Research Laboratories Limited Announces 15th Annual General Meeting and Proposed Registered Office ShiftAGM/EGMlow impact
Cruxal's analysis: Novateor Research Laboratories Limited has issued a notice for its 15th Annual General…
Read the full analysis - Novateor Research Laboratories Limited announces 15th Annual General Meeting for September 29, 2026AGM/EGMlow impact
Cruxal's analysis: Novateor Research Laboratories Limited has scheduled its 15th Annual General Meeting…
Read the full analysis - Novateor Research Laboratories Limited announces reappointment of Secretarial and Internal Auditors for FY 2026-27Company Updatelow impact
Cruxal's analysis: Novateor Research Laboratories Limited has formally approved the reappointment of Mr…
Read the full analysis - Novateor Research Laboratories Limited Announces 15th AGM and Proposed Registered Office ShiftBoard Meetinglow impact
Cruxal's analysis: Novateor Research Laboratories Limited has announced its 15th Annual General Meeting…
Read the full analysis - Novateor Research Laboratories Limited schedules Board Meeting for 3rd September 2026 to discuss Annual General MeetingBoard Meetinglow impact
Cruxal's analysis: Novateor Research Laboratories Limited has issued a formal intimation regarding a Board…
Read the full analysis - Novateor Research Laboratories enters into strategic distribution agreement with Smart Laboratories; secures initial order of 8.40 lakh INRCompany Updatemedium impact
Cruxal's analysis: Novateor Research Laboratories Limited has entered into a Marketer and Manufacturer…
Read the full analysis - Compliance Certificate under Regulation 74(5) of SEBI (DP) Regulation, 2018 for the quarter ended June 30, 2026Company Updatelow impact
This page shows filings on a one-hour delay. Sign in to see them as they land, with Cruxal's analysis of what each one means.
Cruxal publishes market data and coverage for information only. Nothing here is investment advice.